Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Journal of Cardiovascular Translational Research
Erschienen in: Journal of Cardiovascular Translational Research 4/2013

01.08.2013

Biomarkers of Diastolic Dysfunction and Myocardial Fibrosis: Application to Heart Failure with a Preserved Ejection Fraction

verfasst von: Michael R. Zile, Catalin F. Baicu

Erschienen in: Journal of Cardiovascular Translational Research | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Comprehensive diagnostic criteria, accurate prognostic indicators, and effective treatment for patients with heart failure and a preserved ejection fraction (HFpEF) represent a critically important unmet need in cardiovascular medicine. Novel approaches to fill this unmet need are likely to be facilitated by targeting the underlying and unique pathophysiologic mechanisms that characterize patients with HFpEF. Two possible targets include hemodynamic overload evidenced by increased LV diastolic pressure (LVDP) and myocardial fibrosis evidenced by increased extracellular matrix fibrillar collagen. The measurement of LVDP and fibrosis generally requires either invasive procedures and/or complex and sophisticated imaging techniques. However, biomarkers measured in the plasma have been shown to accurately reflect changes in hemodynamic load and myocardial fibrosis and may have important application to the management of patients with HFpEF. The purpose of this review is to describe current and future applications of biomarkers in the management of patients with HFpEF.
Literatur
1.
Owan, T., Hodge, D., Herges, D., et al. (2006). Heart failure with preserved ejection fraction: trends in prevalence and outcomes. The New England Journal of Medicine, 355, 308.CrossRef
2.
Steinberg, B. A., Zhao, X., Heidenreich, P. A., et al. (2012). Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation, 126, 65–75.PubMedCrossRef
3.
Campbell, R., Jhund, P. S., Castagno, D., Hawkins, N. M., Petrie, M. C., & McMurray, J. J. V. (2012). What have we learnt about patients with heart failure and preserved ejection fraction (HF-PEF) from DIG-PEF, CHARM-Preserved and I-Preserve? Journal of the American College of Cardiology, 60, 2349–2356.PubMedCrossRef
4.
Farr, M. J., Lang, C. C., Lamanca, J. J., Zile, M. R., Francis, G., Tavazzi, L., et al. (2008). Cardiopulmonary exercise variables in diastolic versus systolic heart failure. The American Journal of Cardiology, 102, 203–206.PubMedCrossRef
5.
Rector, T. S., Carson, P. E., Anand, I. S., McMurray, J. J., Zile, M. R., McKelvie, R. S., et al. (2012). Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the Minnesota Living with Heart Failure Questionnaire in the I-PRESERVE Trial. Circulation. Heart Failure, 5, 217–225.PubMedCrossRef
6.
Zile, M.R., Kjellstrom, B., Bennett, T., Cho, Y., Baicu, C., Aaron, M., Abraham, W., Bourge, R.C., Kueffer, F. (2013). Effects of exercise on left ventricular systolic and diastolic properties in patients with heart failure and a preserved ejection fraction versus heart failure and a reduced ejection fraction. Circulation. Heart Failure. doi:10.​1161/​CIRCHEARTFAILURE​.​112.​000216.
7.
Little, W. C., & Zile, M. R. (2012). HFpEF: cardiovascular abnormalities not just co-morbidities. Circulation Heart Fail., 5, 669–671.CrossRef
8.
Gaasch, W. H., & Zile, M. R. (2011). Left ventricular structural remodeling in health and disease: with special emphasis on volume, mass, and relative wall thickness. Journal of the American College of Cardiology, 58, 1733–1740.PubMedCrossRef
9.
Zile, M. R., Gottdiener, J. S., Hetzel, S. J., McMurray, J. J., Komajda, M., McKelvie, R., et al. (2011). Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation, 124, 2491–2501.PubMedCrossRef
10.
Gaasch, W. H., Delorey, D. E., Kueffer, F. J., & Zile, M. R. (2009). Distribution of left ventricular ejection fraction in patients with ischemic and hypertensive heart disease and chronic heart failure. The American Journal of Cardiology, 104, 1413–1415.PubMedCrossRef
11.
Aurigemma, G. P., Zile, M. R., & Gaasch, W. H. (2006). Contractile behavior in the left ventricle in diastolic heart failure: with emphasis on regional systolic function. Circulation, 113, 296–304.PubMedCrossRef
12.
Baicu, C. F., Zile, M. R., Aurigemma, G. P., & Gaasch, W. H. (2005). Left ventricular systolic performance, function, and contractility in patients with diastolic heart failure. Circulation, 111, 2306–2312.PubMedCrossRef
13.
Zile, M. R., Baicu, C. F., & Gaasch, W. H. (2004). Diastolic heart failure—abnormalities in active relaxation and passive stiffness of the left ventricle. The New England Journal of Medicine, 350, 1953–1959.PubMedCrossRef
14.
Borbely, A., van der Velden, J., Papp, Z., Bronzwaer, J. G., Edes, I., Stienen, G. J., et al. (2005). Cardiomyocyte stiffness in diastolic heart failure. Circulation, 111, 774–781.PubMedCrossRef
15.
van Heerebeek, L., Hamdani, N., Handoko, M. L., Falcao-Pires, I., Musters, R. J., Kupreishvili, K., et al. (2008). Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation, 117, 43–51.PubMedCrossRef
16.
Westermann, D., Kasner, M., Steendijk, P., Spillmann, F., Riad, A., Weitmann, K., et al. (2008). Role of left ventricular stiffness in heart failure with normal ejection fraction. Circulation, 117, 2051–2060.PubMedCrossRef
17.
Ahmed, A., Rich, M. W., Fleg, J. L., Zile, M. R., Young, J. B., Kitzman, D. W., et al. (2006). Effects of digoxin on morbidity and mortality in diastolic heart failure: The Ancillary Digitalis Investigation Group Trial. Circulation, 114, 397–403.PubMedCrossRef
18.
Yusuf, S., Pfeffer, M. A., Swedberg, K., Granger, C. B., Held, P., McMurray, J. J., et al. (2003). Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM Preserved Trial. The Lancet, 362, 777–781.CrossRef
19.
Cleland, J. G. F., Tendera, M., Adamus, J., Freemantle, N., Polonski, L., & Taylor, J. (2006). The Perindopril in Elderly People with Chronic Heart Failure (PEP-CHF) Study. European Heart Journal, 27, 2338–2345.PubMedCrossRef
20.
Massie, B. M., Carson, P. E., McMurray, J. J., Komajda, M., McKelvie, R., Zile, M. R., et al. (2008). Irbesartan in patients with heart failure and preserved ejection fraction. The New England Journal of Medicine, 359, 2456–2467.PubMedCrossRef
21.
van Veldhuisen, D. J., Cohen-Solal, A., Böhm, M., Anker, S. D., Babalis, D., Roughton, M., et al. (2009). Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data from SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). Journal of the American College of Cardiology, 53, 2150–2158.PubMedCrossRef
22.
McMurray, J. J., Adamopoulos, S., Anker, S. D., Auricchio, A., Bohm, M., Dickstein, K., et al. (2012). ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European Heart Journal, 33, 1787–1847.PubMedCrossRef
23.
Braunwald, E. (2008). Biomarkers in heart failure. The New England Journal of Medicine, 358, 2148–2159.PubMedCrossRef
24.
van Kimmenade, R. R., & Januzzi, J. L. (2012). Emerging biomarkers in heart failure. Clinical Chemistry, 58, 127–138.PubMedCrossRef
25.
Azevedo, C. F., Nigri, M., Higuchi, M. L., Pomerantzeff, P. M., Spina, G. S., Sampaio, R. O., et al. (2010). Prognostic significance of myocardial fibrosis quantification by histopathology and magnetic resonance imaging in patients with severe aortic valve disease. Journal of the American College of Cardiology, 56, 278–287.PubMedCrossRef
26.
Spinale, F. G., Janicki, J. S., & Zile, M. R. (2013). Membrane-associated matrix proteolysis and heart failure. Circulation Research, 112, 195–208.PubMedCrossRef
27.
Spinale, F.G., Zile, M.R. (2013) Heart failure progression and recognition—categorical considerations for translation research. Circ Res (in press).
28.
Wang, T. J., Wollert, K. C., Larson, M. G., Coglianese, E., McCabe, E. L., Cheng, S., et al. (2012). Prognostic utility of novel biomarkers of cardiovascular stress; The Framingham Heart Study. Circulation, 126, 1596–1604.PubMedCrossRef
29.
Wang, Y. C., Yu, C. C., Chiu, F. C., Tsai, C. T., Lai, L. P., Hwang, J. J., et al. (2013). Soluble ST2 as a biomarker for detecting stable heart failure with a normal ejection fraction in hypertensive patients. J Cardiol Fail., 19, 163–168.CrossRef
30.
Bhardwaj, A., & Januzzai, J. L. (2010). ST2: a novel biomarker for heart failure. Expert Review of Molecular Diagnostics, 10, 459–464.PubMedCrossRef
31.
deFilippi, C. R., & Felker, G. M. (2010). Galectin-3 in heart failure—linking fibrosis, remodeling and progression. Euro Cardiology, 6, 33–36.
32.
de Boer, R. A., Lok, D. J., Jaarsma, T., van der Meer, P., Voors, A. A., Hillege, H. L., et al. (2011). Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Annals of Medicine, 43, 60–68.PubMedCrossRef
33.
Yu, L., Ruifrok, W. P., Meissner, M., Bos, E. M., van Goor, H., Sanjabi, B., et al. (2013). Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circulation. Heart Failure, 6, 107–117.PubMedCrossRef
34.
van der Velde, A. R., Gullestad, L., Ueland, T., Aukrust, P., Guo, Y., Adourian, A., et al. (2013). Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH. Circulation Heart Failure, 6, 219–226.PubMedCrossRef
35.
van Veldhuisen, D. J., Linssen, G. C., Jaarsma, T., van Gilst, W. H., Hoes, A. W., Tijssen, J. G., et al. (2013). B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. Journal of the American College of Cardiology, 61, 1498–1506.PubMedCrossRef
36.
Januzzi, J. L., Jr., Rehman, S. U., Mohammed, A. A., Bhardwaj, A., Barajas, L., Barajas, J., et al. (2011). Use of amino-terminal pro-b-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. Journal of the American College of Cardiology, 58, 1881–1889.PubMedCrossRef
37.
Maisel, A. (2011). Biomonitoring and biomarker-guided therapy: the next step in heart failure and biomarker research. Journal of the American College of Cardiology, 58, 1890–1892.PubMedCrossRef
38.
Van Kimmenade, R. R. J., & Januzzi, J. L. (2012). Using natriuretic peptides to ‘guide’ therapy in heart failure. Euro Cardiology., 8, 36–39.
39.
Richards, A. M. (2008). Serial measurements of plasma b-type natriuretic peptides: what do they tell us? Journal of the American College of Cardiology, 52, 1004–1005.PubMedCrossRef
40.
Maisel, A., Barnard, D., Jaski, B., Frivold, G., Marais, J., Azer, M., et al. (2013). Primary results of the HABIT (HF Assessment with Bnp In The Home) Trial. Journal of the American College of Cardiology, 61, 1726–1735.PubMedCrossRef
41.
Lainchbury, J. G., Troughton, R. W., Strangman, K. M., Frampton, C. M., Pilbrow, A., Yandle, T. G., et al. (2009). N-Terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) Trial. Journal of the American College of Cardiology, 55, 53–60.PubMedCrossRef
42.
Weiner, R. B., Baggish, A. L., Chen-Tournoux, A., Marshall, J. E., Gaggin, H. K., Bhardwaj, A., et al. (2013). Improvement in structural and functional echocardiographic parameters during chronic heart failure therapy guided by natriuretic peptides: mechanistic insights from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) Study. European Journal of Heart Failure, 15, 342–351.PubMedCrossRef
43.
Anand, I. S., Rector, T. S., Cleland, J. G., Kuskowski, M., McKelvie, R. S., Persson, H., et al. (2011). Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE Trial. Circulation. Heart Failure, 4, 569–577.PubMedCrossRef
44.
McKelvie, R. S., Komajda, M., McMurray, J., Zile, M. R., Ptaszynska, A., Donovan, M., et al. (2010). Baseline plasma NT-proBNP and clinical characteristics: results from the Irbesartan In Heart Failure With Preserved Ejection Fraction Trial. Journal of Cardiac Failure, 16(2), 128–134.PubMedCrossRef
45.
Jhund PS, Anand IS, Komajda M, McKelvie RS, Zile MR, Massie B, Carson PE, McMurray JJV. (2013). Change in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-PRESERVE study. Eur Heart J (in press).
46.
Iwanaga, Y., Nishi, I., Furuichi, S., Noguchi, T., Sase, K., Kihara, Y., et al. (2006). B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. Journal of the American College of Cardiology, 47(4), 742–748.PubMedCrossRef
47.
Zile, M. R., Bennett, T. D., St. John Sutton, M., Cho, Y. K., Adamson, P. B., Aaron, M. F., et al. (2008). Transition from chronic compensated to acute decompensated heart failure: pathophysiologic insights obtained from continuous monitoring of intracardiac pressures. Circulation, 118(14), 1433–1441.PubMedCrossRef
48.
Stevenson, L. W., Zile, M., Bennett, T. D., Kueffer, F. J., Jessup, M. L., Adamson, P., et al. (2010). Chronic ambulatory intracardiac pressures and future heart failure events. Circulation. Heart Failure, 3, 580–587.PubMedCrossRef
49.
Abraham, W. T., Adamson, P. B., Bourge, R. C., Aaron, M. F., Costanzo, M. R., Stevenson, L. W., et al. (2011). Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. The Lancet, 377, 658–666.CrossRef
50.
Solomon, S. D., Zile, M. R., Pieske, B., Voors, A., Shah, A., Kraigher-Krainer, E., et al. (2012). The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase II randomized-controlled trial. The Lancet, 380, 1387–1395.CrossRef
51.
Chen, H. H., Glockner, J. F., Schirger, J. A., Cataliotti, A., Redfield, M. M., & Jr. Burnett, J. C. (2012). Novel protein therapeutics for systolic heart failure: chronic subcutaneous B-type natriuretic peptide. Journal of the American College of Cardiology, 60, 2305–2312.PubMedCrossRef
52.
O’Connor, C. M., Starling, R. C., Hernandez, A. F., et al. (2011). Effect of nesiritide in patients with acute decompensated heart failure. The New England Journal of Medicine, 365, 32–43.PubMedCrossRef
53.
Baicu, C. F., Li, J., Zhang, Y., Kasiganesan, H., Cooper, G., Zile, M. R., et al. (2012). Time course of right ventricular pressure-overload induced myocardial fibrosis: relationship to changes in fibroblast dependent post-synthetic procollagen processing. American Journal of Physiology-Heart and Circulatory Physiology, 303, H1128–H1134. PMCID: In Progress.PubMedCrossRef
54.
Zile, M. R., Baicu, C. F., Stroud, R. E., Van Laer, A., Arroyo, J., Mukherjee, R., et al. (2012). Pressure-overload department membrane-type 1 matrix metalloproteinase induction: relationship to LV remodeling and fibrosis. American Journal of Physiology - Heart and Circulatory Physiology, 302, H1429–H1437.PubMedCrossRef
55.
Zile, M. R., DeSantis, S. M., Baicu, C. F., Stroud, R. E., Thompson, S. B., McClure, C. D., et al. (2011). Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure. Circulation. Heart Failure, 4, 246–256.PubMedCrossRef
56.
Martos, R., Baugh, J., Ledwidge, M., O'Loughlin, C., Conlon, C., Patle, A., et al. (2007). Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation, 115, 888–895.PubMedCrossRef
57.
López, B., González, A., & Díez, J. (2010). Circulating biomarkers of collagen metabolism in cardiac diseases. Circulation, 121, 1645–1654.PubMedCrossRef
58.
González, A., López, B., Querejeta, R., Zubillaga, E., Echeverría, T., & Díez, J. (2010). Filling pressures and collagen metabolism in hypertensive patients with heart failure and normal ejection fraction. Hypertension, 55, 1418–1424.PubMedCrossRef
59.
Krum, H., Elsik, M., Schneider, H. G., Ptaszynska, A., Black, M., Carson, P., et al. (2011). Relation of peripheral collagen markers to death and hospitalisation in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen sub-study. Cir Heart Fail, 4, 561–568.CrossRef
60.
Bradshaw, A. D., Baicu, C. F., Rentz, T. J., Van Laer, A. O., Boggs, J., Lacy, J. M., et al. (2009). Pressure-overload induced alterations in fibrillar collagen content and myocardial diastolic function: role of SPARC in post-synthetic procollagen processing. Circulation, 119, 269–280.PubMedCrossRef
61.
Bradshaw, A. D., Baicu, C. F., Rentz, T. J., Van Laer, A. O., Bonnema, D. D., & Zile, M. R. (2010). Age-dependent alterations in fibrillar collagen content and myocardial diastolic function: role of SPARC in post-synthetic procollagen processing. American Journal of Physiology - Heart and Circulatory Physiology, 298, H614–H622.PubMedCrossRef
62.
Baicu, C. F., Zhang, Y., Van Laer, A. O., Renaud, L., Zile, M. R., & Bradshaw, A. D. (2012). Effects of the absence of procollagen C-endopeptidase enhancer-2 (PCOLCE-2) on myocardial collagen accumulation in chronic pressure-overload. American Journal of Physiology - Heart and Circulatory Physiology, 303, H234–H240.PubMedCrossRef
63.
Bartunek, J., Delrue, L., Van Durme, F., Muller, O., Casselman, F., De Wiest, B., et al. (2008). Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. Journal of the American College of Cardiology, 52(25), 2166–2174.PubMedCrossRef
64.
Manzano-Fernández, S., Mueller, T., Pascual-Figal, D., Truong, Q. A., & Januzzi, J. L. (2011). Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. The American Journal of Cardiology, 107(2), 259–267.PubMedCrossRef
65.
Rehman, S. U., Mueller, T., & Januzzi, J. L., Jr. (2008). Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. Journal of the American College of Cardiology, 52(18), 1458–1465.PubMedCrossRef
66.
Gopal, D. M., Kommineni, M., Ayalon, N., Christian Koelbl, C., Rivka Ayalon, R., Andreia Biolo, A., et al. (2012). Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure. J Am Heart Assoc., 1, e000760. doi:10.​1161/​JAHA.​112.​000760.PubMedCrossRef
67.
Shah, R. V., Chen-Tournoux, A. A., Picard, M. H., van Kimmenade, R. R., & Januzzi, J. L. (2010). Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. European Journal of Heart Failure, 12(8), 826–832.PubMedCrossRef
68.
van Kimmenade, R. R., Januzzi, J. L., Jr., Ellinor, P. T., Sharma, U. C., Bakker, J. A., Low, A. F., et al. (2006). Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. Journal of the American College of Cardiology, 48(6), 1217–1224.PubMedCrossRef
69.
de Boer RA, Van Veldhuisen DJ, deFilippi C, Muntendam P, Adourian AS, Guo Y, Januzzi JL. (2011). Plasma galectin-3 is associated with near-term rehospitalization in heart failure. Poster Abstract #297, 15th Annual Scientific Meeting of the Heart Failure Society of America, Boston, MA, 18–21 Sept
70.
Martos, R., Baugh, J., Ledwidge, M., O'Loughlin, C., Murphy, N. F., Conlon, C., et al. (2009). Diagnosis of heart failure with preserved ejection fraction: improved accuracy with the use of markers of collagen turnover. European Journal of Heart Failure, 11(2), 191–197.PubMedCrossRef
71.
Barasch, E., Gottdiener, J. S., Aurigemma, G., Kitzman, D. W., Han, J., Kop, W. J., et al. (2009). Association between elevated fibrosis markers and heart failure in the elderly: the Cardiovascular Health Study. Circulation. Heart Failure, 2(4), 303–310.PubMedCrossRef
72.
Kitahara, T., Takeishi, Y., Arimoto, T., Niizeki, T., Koyama, Y., Sasaki, T., et al. (2007). Serum carboxy-terminal telopeptide of type I collagen (ICTP) predicts cardiac events in chronic heart failure patients with preserved left ventricular systolic function. Circulation Journal, 71(6), 929–935.PubMedCrossRef
73.
Barasch, E., Gottdiener, J. S., Aurigemma, G., Kitzman, D. W., Han, J., Kop, W. J., et al. (2011). The relationship between serum markers of collagen turnover and cardiovascular outcome in the elderly: the Cardiovascular Health Study. Circulation. Heart Failure, 4(6), 733–739.PubMedCrossRef
74.
Ahmed, S. H., Clark, L. L., Pennington, W. R., Webb, C. S., Bonnema, D. D., Leonardi, A. H., et al. (2006). Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation, 113(17), 2089–2096.PubMedCrossRef
Metadaten
Titel
Biomarkers of Diastolic Dysfunction and Myocardial Fibrosis: Application to Heart Failure with a Preserved Ejection Fraction
verfasst von
Michael R. Zile
Catalin F. Baicu
Publikationsdatum
01.08.2013
Verlag
Springer US
Erschienen in
Journal of Cardiovascular Translational Research / Ausgabe 4/2013
Print ISSN: 1937-5387
Elektronische ISSN: 1937-5395
DOI
https://doi.org/10.1007/s12265-013-9472-1

Weitere Artikel der Ausgabe 4/2013

Journal of Cardiovascular Translational Research 4/2013 Zur Ausgabe

OriginalPaper

Method for Percutaneously Introducing, and Removing, Anatomical Stenosis of Predetermined Severity In Vivo: The “Stenotic Stent”

OriginalPaper

Multi-Ligand Poly(l-Lactic-co-Glycolic Acid) Nanoparticles Inhibit Activation of Endothelial Cells

OriginalPaper

Attenuation of Monocyte Chemotaxis—A Novel Anti-inflammatory Mechanism of Action for the Cardio-protective Hormone B-Type Natriuretic Peptide

OriginalPaper

Development of a Swine Model of Left Bundle Branch Block for Experimental Studies of Cardiac Resynchronization Therapy

OriginalPaper

Endothelial Cell Death and Intimal Foam Cell Accumulation in the Coronary Artery of Infected Hypercholesterolemic Minipigs

OriginalPaper

ST2 as a Cardiovascular Risk Biomarker: From the Bench to the Bedside

Neu im Fachgebiet Kardiologie

Ist Fasten vor Koronarinterventionen wirklich nötig?

04.06.2024 Interventionelle Verfahren in der Kardiologie Nachrichten

Wenn Eingriffe wie eine Koronarangiografie oder eine Koronarangioplastie anstehen, wird häufig empfohlen, in den Stunden zuvor nüchtern zu bleiben. Ein französisches Forscherteam hat diese Maßnahme hinterfragt.

PET kann infarktgefährdete Koronararterien entdecken

04.06.2024 Koronare Herzerkrankung Nachrichten

Der Nachweis aktiver Plaques mittels 18F-Natriumfluorid-PET hilft nicht nur, infarktgefährdete Patienten, sondern auch infarktgefährdete Koronararterien zu erkennen. Von einer gezielten Behandlung vulnerabler Plaques ist man trotzdem weit entfernt.

GLP-1-Agonist Semaglutid wirkt kardio- und nephroprotektiv

03.06.2024 Semaglutid Nachrichten

Der GLP-1-Agonist Semaglutid hat in der FLOW-Studie bewiesen, dass sich damit die Progression chronischer Nierenerkrankungen bei Patienten mit Typ-2-Diabetes bremsen lässt. Auch in kardiovaskulärer Hinsicht war die Therapie erfolgreich.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise